Chad Harman CEO at Psycheceutical on Neurodirect-Delivered Ketamine

In this episode, guest Chad Harman discusses the innovative Neurodirect technology, invented by Dr. Ronald Aungdon, a leading neuropsychiatrist and neurologist. With a proven track record of conducting over 50 clinical trials and securing FDA approval for more than 30 of them, Dr. Aungdon’s latest invention addresses a significant gap in the delivery of neurological medications.In the opening segment of this episode, I delve into a fascinating discussion about an innovative medical treatment, Neurodirect technology. Admittedly, I approached the topic with a healthy dose of skepticism. As a newcomer to the concept, I questioned the effectiveness of this novel approach to neurological medication delivery. However, as I delved deeper into the science underpinning the technology, learned about its FDA approval, and understood its compelling safety profile, my perspective began to shift. What unfolded was a journey from skepticism to intrigue, as I uncovered the profound potential that this groundbreaking treatment holds for the future of medicine.Harman explains that the Neurodirect technology allows for the application of neuroeffective compounds topically, specifically at the back of the neck, to bypass the systemic side effects commonly associated with traditional neurological medications. This targeted application has led to profound effects. The first patented application of this technology was with sumatryptin, a drug used for severe migraines. Traditional oral administration of sumatryptin often left residual symptoms and took 35 to 45 minutes to work. However, with the Neurodirect delivery platform, the effects are immediate, leading to almost complete remission of symptoms within minutes.The benefits of Neurodirect don't stop there. Dr. Aungdon has been using this technology for topical ketamine administration for over a year, with promising results. A recent peer-reviewed article in Drug Delivery magazine reported on an observational study involving 100 patients suffering from severe PTSD and treatment-resistant depression. The study found that 80% of these patients responded favorably to Neurodirect-delivered ketamine, thus offering a new, safe, and effective method of delivering neuroeffective compounds.Harman also highlights the potential benefits of this technology in addressing the current epidemic of anxiety and panic disorders, exacerbated by factors such as physician and nurse burnout during the pandemic. The ability to deliver fast relief through topical administration could revolutionize patient care and provide a breakthrough in the delivery of neurological treatments.Please visit our podcast website: https://therehab.com and our practice website: https://drleeds.com